Source link : https://www.newshealth.biz/health-news/two-million-cancers-casgevy-okd-for-thalassemia-rectal-exams-and-prostate-cancer/
While cancer mortality continues to decline, the number of new cases is projected to top 2 million in 2024, according to the American Cancer Society’s annual report on cancer statistics. The FDA approved exagamglogene autotemcel (Casgevy) for transfusion-dependent beta thalassemia in patients 12 years and older, maker Vertex announced. This follows last month’s approval of […]
Author : News Health
Publish date : 2024-01-19 14:30:32
Copyright for syndicated content belongs to the linked Source.